Compare LCTX & DSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | DSP |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 198.1M |
| IPO Year | N/A | 2021 |
| Metric | LCTX | DSP |
|---|---|---|
| Price | $1.65 | $11.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $4.25 | ★ $18.50 |
| AVG Volume (30 Days) | ★ 1.3M | 229.2K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.49 |
| EPS | N/A | ★ 0.10 |
| Revenue | $10,816,000.00 | ★ $324,131,000.00 |
| Revenue This Year | $6.32 | $17.79 |
| Revenue Next Year | $124.49 | $17.72 |
| P/E Ratio | ★ N/A | $121.66 |
| Revenue Growth | ★ 24.05 | 22.97 |
| 52 Week Low | $0.37 | $8.11 |
| 52 Week High | $2.09 | $26.33 |
| Indicator | LCTX | DSP |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 63.23 |
| Support Level | $1.63 | $11.54 |
| Resistance Level | $1.77 | $12.15 |
| Average True Range (ATR) | 0.08 | 0.49 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 16.67 | 60.47 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.